Safety creatinine clearance level for platinum chemotherapy in lung cancer patients

  • Authors:
    • Gen Ohara
    • Kunihiko Miyazaki
    • Koichi Kurishima
    • Katsunori Kagohashi
    • Hiroichi Ishikawa
    • Hiroaki Satoh
    • Nobuyuki Hizawa
  • View Affiliations

  • Published online on: November 16, 2011     https://doi.org/10.3892/ol.2011.486
  • Pages: 311-314
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study was carried out to evaluate whether measured‑creatinine clearance (measured‑CrCl) and Cockcroft and Gault-CrCl (CG‑CrCl) are capable of appropriately detecting a decline in renal function in lung cancer patients, including elderly patients, and to clarify a CrCl level with which to discriminate between patients with or without renal impairment. The measured‑CrCl prior and subsequent to platinum‑based chemotherapy of lung cancer patients was retrospectively analyzed. Measured‑CrCl and CG‑CrCl were evaluated prior and subsequent to platinum‑based chemotherapy for lung cancer. Measured-CrCl and CG‑CrCl in 59 lung cancer patients including 25 patients aged ≥65 years were retrospectively analyzed. In patients treated with carboplatin‑based chemotherapy, measured‑CrCl was indicative of a decline in renal function, whereas CG‑CrCl was not. The optimal measured-CrCl level was <60 ml/min post-pretreatment and >90 ml/­min at pre-treatment. In cases with pre‑treatment measured-CrCl levels of >90 ml/­min, favorable renal function is necessary in order to carry out platinum-based chemotherapy in lung cancer patients, including the elderly.
View Figures
View References

Related Articles

Journal Cover

February 2012
Volume 3 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ohara G, Miyazaki K, Kurishima K, Kagohashi K, Ishikawa H, Satoh H and Hizawa N: Safety creatinine clearance level for platinum chemotherapy in lung cancer patients. Oncol Lett 3: 311-314, 2012.
APA
Ohara, G., Miyazaki, K., Kurishima, K., Kagohashi, K., Ishikawa, H., Satoh, H., & Hizawa, N. (2012). Safety creatinine clearance level for platinum chemotherapy in lung cancer patients. Oncology Letters, 3, 311-314. https://doi.org/10.3892/ol.2011.486
MLA
Ohara, G., Miyazaki, K., Kurishima, K., Kagohashi, K., Ishikawa, H., Satoh, H., Hizawa, N."Safety creatinine clearance level for platinum chemotherapy in lung cancer patients". Oncology Letters 3.2 (2012): 311-314.
Chicago
Ohara, G., Miyazaki, K., Kurishima, K., Kagohashi, K., Ishikawa, H., Satoh, H., Hizawa, N."Safety creatinine clearance level for platinum chemotherapy in lung cancer patients". Oncology Letters 3, no. 2 (2012): 311-314. https://doi.org/10.3892/ol.2011.486